Answers are grounded in this paper and cite their sources.
ACY-1215 is an oral selective HDAC6 inhibitor that was safe in patients with relapsed and refractory lymphoid malignancies and led to disease stabilization in half of the evaluable patients.
No takes yet. Share an insight, caveat, or question.
Amengual et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: